Gastroenterology

The company expects to continue to study the potential inflammatory bowel disease treatment.

Genotype F was the common genotype found at 5.73 per 1000 person-years of follow-up.

Patients with IBD, rheumatoid arthritis, and psoriasis are commonly treated using biologic agents such as infliximab, tofacitinib, and ustekinumab.

The treatment was associated with an increased risk of C difficile colitis.

The issuance comes within a week of the planned PDUFA date for the drug's possible indication as an adult CKD therapy.

The researchers found sero-protection rate at 12-month was significantly higher in the ID arm compared to the IM cohort.

This patient group was at an increased risk for future exposure to systemic corticosteroids and anti-TNF biologics.

Biologic use was not associated with an increased risk of hepatitis B virus flares.

Patients with IBD have an increased risk of developing a C difficile infection in comparison to the general population.

About 25% of IBD patients with CDI had a history of antibiotic use.

One theory as to why IBD patients are more susceptible to CDI is the use of immunosuppressant treatments.

96.4% of patients in symptomatic remission at week 152 were corticosteroid-free.

Several different treatments appear to be efficacious in this patient population.

A maternal-infant HCV linkage program in combination with a multidisciplinary clinic to collocate mother and infant care was implemented in 2016.

The overall serum anti-toxin A and B antibody levels were similar at baseline between immunocompromised hosts and non-immunocompromised hosts.

Telemedicine could be useful if it is added to regimen of in-person health care visits.

Cases were identified by searching the Veterans Affairs Corporate Data Warehouse.

The treatment resulted in a significant reduction in expression of genes representing T & B lymphocytes, plasma cells/plasmablasts, and myeloid cells.

IDSA and SHEA released 3 new evidence-based recommendations for treating CDI.

Only 5 patients treated with antibiotic prophylaxis developed bacteremia.

Diabetes, obesity, and older age are considered main risk factors that yield non-responses to different HBV vaccines.

Nearly half of all never C difficile cases are found in nursing home communities.